Involvement of HIF1 α/Reg protein in the regulation of HMGB3 in myocardial infarction
CONCLUSION: HMGB3 plays a dual role during the progression of myocardial ischemia and infarction. Clinically, post-myocardial infarction HMGB3 induced sterile inflammation needs to be tightly controlled, as it plays both a pro-inflammatory role and improves cardiac function during the cardiac remodeling phase.PMID:37467910 | DOI:10.1016/j.vph.2023.107197 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - July 19, 2023 Category: Drugs & Pharmacology Authors: Amit Manhas Dipti Tripathi Kumaravelu Jagavelu Source Type: research
Sacubitril/valsartan effects on arrhythmias and left ventricular remodelling in heart failure: An observational study
CONCLUSION: Sacubitril/valsartan reduced the number of premature ventricular complexes and increased the percentage of biventricular pacing in a cohort of HFrEF patients already on optimal medical therapy. PVC reduction did not correlate with reverse left ventricular remodelling. Whether sacubitril/valsartan has any direct antiarrhythmic effects is an issue to be better explored in future studies.PMID:37467909 | DOI:10.1016/j.vph.2023.107196 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - July 19, 2023 Category: Drugs & Pharmacology Authors: Mauro Acquaro Laura Scelsi Beatrice Pasotti Alessandro Seganti Marcello Spolverini Alessandra Greco Sandra Schirinzi Annalisa Turco Antonio Sanzo Simone Savastano Roberto Rordorf Stefano Ghio Source Type: research
Involvement of HIF1 α/Reg protein in the regulation of HMGB3 in myocardial infarction
CONCLUSION: HMGB3 plays a dual role during the progression of myocardial ischemia and infarction. Clinically, post-myocardial infarction HMGB3 induced sterile inflammation needs to be tightly controlled, as it plays both a pro-inflammatory role and improves cardiac function during the cardiac remodeling phase.PMID:37467910 | DOI:10.1016/j.vph.2023.107197 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - July 19, 2023 Category: Drugs & Pharmacology Authors: Amit Manhas Dipti Tripathi Kumaravelu Jagavelu Source Type: research
Sacubitril/valsartan effects on arrhythmias and left ventricular remodelling in heart failure: An observational study
CONCLUSION: Sacubitril/valsartan reduced the number of premature ventricular complexes and increased the percentage of biventricular pacing in a cohort of HFrEF patients already on optimal medical therapy. PVC reduction did not correlate with reverse left ventricular remodelling. Whether sacubitril/valsartan has any direct antiarrhythmic effects is an issue to be better explored in future studies.PMID:37467909 | DOI:10.1016/j.vph.2023.107196 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - July 19, 2023 Category: Drugs & Pharmacology Authors: Mauro Acquaro Laura Scelsi Beatrice Pasotti Alessandro Seganti Marcello Spolverini Alessandra Greco Sandra Schirinzi Annalisa Turco Antonio Sanzo Simone Savastano Roberto Rordorf Stefano Ghio Source Type: research
Involvement of HIF1 α/Reg protein in the regulation of HMGB3 in myocardial infarction
CONCLUSION: HMGB3 plays a dual role during the progression of myocardial ischemia and infarction. Clinically, post-myocardial infarction HMGB3 induced sterile inflammation needs to be tightly controlled, as it plays both a pro-inflammatory role and improves cardiac function during the cardiac remodeling phase.PMID:37467910 | DOI:10.1016/j.vph.2023.107197 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - July 19, 2023 Category: Drugs & Pharmacology Authors: Amit Manhas Dipti Tripathi Kumaravelu Jagavelu Source Type: research
Sacubitril/valsartan effects on arrhythmias and left ventricular remodelling in heart failure: An observational study
CONCLUSION: Sacubitril/valsartan reduced the number of premature ventricular complexes and increased the percentage of biventricular pacing in a cohort of HFrEF patients already on optimal medical therapy. PVC reduction did not correlate with reverse left ventricular remodelling. Whether sacubitril/valsartan has any direct antiarrhythmic effects is an issue to be better explored in future studies.PMID:37467909 | DOI:10.1016/j.vph.2023.107196 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - July 19, 2023 Category: Drugs & Pharmacology Authors: Mauro Acquaro Laura Scelsi Beatrice Pasotti Alessandro Seganti Marcello Spolverini Alessandra Greco Sandra Schirinzi Annalisa Turco Antonio Sanzo Simone Savastano Roberto Rordorf Stefano Ghio Source Type: research
Involvement of HIF1 α/Reg protein in the regulation of HMGB3 in myocardial infarction
CONCLUSION: HMGB3 plays a dual role during the progression of myocardial ischemia and infarction. Clinically, post-myocardial infarction HMGB3 induced sterile inflammation needs to be tightly controlled, as it plays both a pro-inflammatory role and improves cardiac function during the cardiac remodeling phase.PMID:37467910 | DOI:10.1016/j.vph.2023.107197 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - July 19, 2023 Category: Drugs & Pharmacology Authors: Amit Manhas Dipti Tripathi Kumaravelu Jagavelu Source Type: research
Sacubitril/valsartan effects on arrhythmias and left ventricular remodelling in heart failure: An observational study
CONCLUSION: Sacubitril/valsartan reduced the number of premature ventricular complexes and increased the percentage of biventricular pacing in a cohort of HFrEF patients already on optimal medical therapy. PVC reduction did not correlate with reverse left ventricular remodelling. Whether sacubitril/valsartan has any direct antiarrhythmic effects is an issue to be better explored in future studies.PMID:37467909 | DOI:10.1016/j.vph.2023.107196 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - July 19, 2023 Category: Drugs & Pharmacology Authors: Mauro Acquaro Laura Scelsi Beatrice Pasotti Alessandro Seganti Marcello Spolverini Alessandra Greco Sandra Schirinzi Annalisa Turco Antonio Sanzo Simone Savastano Roberto Rordorf Stefano Ghio Source Type: research
Involvement of HIF1 α/Reg protein in the regulation of HMGB3 in myocardial infarction
CONCLUSION: HMGB3 plays a dual role during the progression of myocardial ischemia and infarction. Clinically, post-myocardial infarction HMGB3 induced sterile inflammation needs to be tightly controlled, as it plays both a pro-inflammatory role and improves cardiac function during the cardiac remodeling phase.PMID:37467910 | DOI:10.1016/j.vph.2023.107197 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - July 19, 2023 Category: Drugs & Pharmacology Authors: Amit Manhas Dipti Tripathi Kumaravelu Jagavelu Source Type: research
Sacubitril/valsartan effects on arrhythmias and left ventricular remodelling in heart failure: An observational study
CONCLUSION: Sacubitril/valsartan reduced the number of premature ventricular complexes and increased the percentage of biventricular pacing in a cohort of HFrEF patients already on optimal medical therapy. PVC reduction did not correlate with reverse left ventricular remodelling. Whether sacubitril/valsartan has any direct antiarrhythmic effects is an issue to be better explored in future studies.PMID:37467909 | DOI:10.1016/j.vph.2023.107196 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - July 19, 2023 Category: Drugs & Pharmacology Authors: Mauro Acquaro Laura Scelsi Beatrice Pasotti Alessandro Seganti Marcello Spolverini Alessandra Greco Sandra Schirinzi Annalisa Turco Antonio Sanzo Simone Savastano Roberto Rordorf Stefano Ghio Source Type: research
Involvement of HIF1 α/Reg protein in the regulation of HMGB3 in myocardial infarction
CONCLUSION: HMGB3 plays a dual role during the progression of myocardial ischemia and infarction. Clinically, post-myocardial infarction HMGB3 induced sterile inflammation needs to be tightly controlled, as it plays both a pro-inflammatory role and improves cardiac function during the cardiac remodeling phase.PMID:37467910 | DOI:10.1016/j.vph.2023.107197 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - July 19, 2023 Category: Drugs & Pharmacology Authors: Amit Manhas Dipti Tripathi Kumaravelu Jagavelu Source Type: research
Prolonged impact of anti-cancer therapy on endothelial function and arterial stiffness in breast cancer patients
CONCLUSIONS: In patients with breast cancer, there is progression of endothelial dysfunction and arteriosclerosis up to 15 months following initiation of anthracycline-based chemotherapy. Trastuzumab has no additive effect on endothelial function or arterial stiffness.PMID:37455009 | DOI:10.1016/j.vph.2023.107195 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - July 16, 2023 Category: Drugs & Pharmacology Authors: Maria Anastasiou Evangelos Oikonomou Panagiotis Theofilis George Angelos Papamikroulis Maria Gazouli Konstantinos Kalogeras Stavroula Lygkoni Theodoros Pesiridis Athina Goliopoulou Alkistis Papatheodoridi Amanda Psyrri Flora Zagouri Gerasimos Siasos Dimit Source Type: research
Prolonged impact of anti-cancer therapy on endothelial function and arterial stiffness in breast cancer patients
CONCLUSIONS: In patients with breast cancer, there is progression of endothelial dysfunction and arteriosclerosis up to 15 months following initiation of anthracycline-based chemotherapy. Trastuzumab has no additive effect on endothelial function or arterial stiffness.PMID:37455009 | DOI:10.1016/j.vph.2023.107195 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - July 16, 2023 Category: Drugs & Pharmacology Authors: Maria Anastasiou Evangelos Oikonomou Panagiotis Theofilis George Angelos Papamikroulis Maria Gazouli Konstantinos Kalogeras Stavroula Lygkoni Theodoros Pesiridis Athina Goliopoulou Alkistis Papatheodoridi Amanda Psyrri Flora Zagouri Gerasimos Siasos Dimit Source Type: research
Prolonged impact of anti-cancer therapy on endothelial function and arterial stiffness in breast cancer patients
CONCLUSIONS: In patients with breast cancer, there is progression of endothelial dysfunction and arteriosclerosis up to 15 months following initiation of anthracycline-based chemotherapy. Trastuzumab has no additive effect on endothelial function or arterial stiffness.PMID:37455009 | DOI:10.1016/j.vph.2023.107195 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - July 16, 2023 Category: Drugs & Pharmacology Authors: Maria Anastasiou Evangelos Oikonomou Panagiotis Theofilis George Angelos Papamikroulis Maria Gazouli Konstantinos Kalogeras Stavroula Lygkoni Theodoros Pesiridis Athina Goliopoulou Alkistis Papatheodoridi Amanda Psyrri Flora Zagouri Gerasimos Siasos Dimit Source Type: research
Prostacyclin mimetics inhibit DRP1-mediated pro-proliferative mitochondrial fragmentation in pulmonary arterial hypertension
In this study, we confirmed the previously reported increase in DRP1-mediated mitochondrial hyper-fragmentation in PAH PASMCs. We then showed that the prostacyclin mimetic treprostinil signals via either the Gs-coupled IP or EP2 receptor to inhibit mitochondrial fragmentation and the associated hyper-proliferation in a manner analogous to the DRP1 inhibitor Mdivi-1. We also showed that treprostinil recruits either the IP or EP2 receptor to activate PKA and induce the phosphorylation of DRP1 at the inhibitory residue S637 and inhibit that at the stimulatory residue S616, both of which are suggestive of reduced DRP1 fission ...
Source: Vascular Pharmacology - July 13, 2023 Category: Drugs & Pharmacology Authors: Jeries Abu-Hanna Evangelos Anastasakis Jigisha A Patel Mohammad Mahmoud Rajab Eddama Christopher P Denton Jan-Willem Taanman David Abraham Lucie H Clapp Source Type: research
